168 related articles for article (PubMed ID: 24965716)
21. Trend Analysis of FDA Warning Letters Issued to Medical Products About Violations to Current Good Manufacturing Practices (CGMP) Between 2007 and 2014.
Wang L; Zheng H; Ren X; Sun H
Ther Innov Regul Sci; 2016 May; 50(3):312-318. PubMed ID: 30227064
[TBL] [Abstract][Full Text] [Related]
22. FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violation.
Stewart KA; Neumann PJ
Value Health; 2002; 5(5):390-7. PubMed ID: 12201856
[TBL] [Abstract][Full Text] [Related]
23. Does Sackett foreshadow the end of non-reviewability for FDA warning letters?
DeRuyter K
Food Drug Law J; 2013; 68(3):241-58, i. PubMed ID: 24640609
[TBL] [Abstract][Full Text] [Related]
24. Views of the process and content of ethical reviews of HIV vaccine trials among members of US institutional review boards and South African research ethics committees.
Klitzman R
Dev World Bioeth; 2008 Dec; 8(3):207-18. PubMed ID: 19046258
[TBL] [Abstract][Full Text] [Related]
25. How confidential trial negotiations and agreements between the Food and Drug Administration and sponsors marginalize local institutional review boards, and what to do about it.
Mann H
Am J Bioeth; 2006; 6(3):22-4; discussion W49-50. PubMed ID: 16754442
[No Abstract] [Full Text] [Related]
26. Analysis of US Food and Drug Administration Warning Letters: False Promotional Claims Relating to Prescription and Over-the-Counter Medications.
Salas M; Martin M; Pisu M; McCall E; Zuluaga A; Glasser SP
Pharmaceut Med; 2008 Mar; 22(2):. PubMed ID: 24353430
[TBL] [Abstract][Full Text] [Related]
27. Research misconduct identified by the US Food and Drug Administration: out of sight, out of mind, out of the peer-reviewed literature.
Seife C
JAMA Intern Med; 2015 Apr; 175(4):567-77. PubMed ID: 25664866
[TBL] [Abstract][Full Text] [Related]
28. FDA actions against health economic promotions, 2002-2011.
Neumann PJ; Bliss SK
Value Health; 2012; 15(6):948-53. PubMed ID: 22999146
[TBL] [Abstract][Full Text] [Related]
29. Medical device warning letter pilot. Food and Drug Administration, HHS. Notice.
Fed Regist; 1999 Mar; 64(44):11018-23. PubMed ID: 10557622
[TBL] [Abstract][Full Text] [Related]
30. FDA Warning Letters: A Retrospective Analysis of Letters Issued to Pharmaceutical Companies from 2010-2020.
Rathore AS; Li Y; Chhabra H; Lohiya A
J Pharm Innov; 2022 Aug; ():1-10. PubMed ID: 35992018
[TBL] [Abstract][Full Text] [Related]
31. A clinical trial primer: historical perspective and modern implementation.
Karsh LI
Urol Oncol; 2012; 30(4 Suppl):S28-32. PubMed ID: 22795078
[TBL] [Abstract][Full Text] [Related]
32. Current issues in clinical research and the development of new pharmaceuticals.
Goldhammer A
Account Res; 2001; 8(4):283-91. PubMed ID: 12481798
[TBL] [Abstract][Full Text] [Related]
33. Food and Drug Administration guidance: supervisory responsibilities of investigators.
Anderson C; Young PA; Berenbaum A
J Diabetes Sci Technol; 2011 Mar; 5(2):433-8. PubMed ID: 21527116
[TBL] [Abstract][Full Text] [Related]
34. An analysis of the warning letters issued by the FDA to pharmaceutical manufacturers regarding misleading health outcomes claims.
Chatterjee S; Patel HK; Sansgiry SS
Pharm Pract (Granada); 2012 Oct; 10(4):194-8. PubMed ID: 24155837
[TBL] [Abstract][Full Text] [Related]
35. Unicorn Poo and Blessed Waters: COVID-19 Quackery and FDA Warning Letters.
Bramstedt KA
Ther Innov Regul Sci; 2021 Jan; 55(1):239-244. PubMed ID: 33001378
[TBL] [Abstract][Full Text] [Related]
36. Medical device warning letter draft pilot; availability--FDA. Notice.
Fed Regist; 1998 Aug; 63(166):45821-5. PubMed ID: 10182695
[TBL] [Abstract][Full Text] [Related]
37. The interrelationship of sponsors, clinical investigators, and institutional review boards.
Kirsch TJ
Drug Inf J; 1987; 21(2):127-31. PubMed ID: 10282113
[TBL] [Abstract][Full Text] [Related]
38. Toward protecting the safety of participants in clinical trials.
Califf RM; Morse MA; Wittes J; Goodman SN; Nelson DK; DeMets DL; Iafrate RP; Sugarman J
Control Clin Trials; 2003 Jun; 24(3):256-71. PubMed ID: 12757992
[TBL] [Abstract][Full Text] [Related]
39. Justification and authority in institutional review board decision letters.
Clapp JT; Gleason KA; Joffe S
Soc Sci Med; 2017 Dec; 194():25-33. PubMed ID: 29059597
[TBL] [Abstract][Full Text] [Related]
40. Content Analysis of 2012-2019 FDA Warning Letters and Notices of Violations using the Economic, Clinical, and Humanistic Outcomes (ECHO) Model.
Mohite N; Funtanilla V; Muzumdar J; Park T
Innov Pharm; 2021; 12(1):. PubMed ID: 34007685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
